Study Overview
Objective: Validate cGAS-STING pathway activation as a mechanistically significant driver of dopaminergic neurodegeneration in PD and test therapeutic targeting with cGAS/STING inhibitors.
Hypothesis: Chronic cGAS-STING activation in microglia and neurons driven by cytosolic DNA accumulation (primarily mitochondrial DNA) triggers type I interferon responses that accelerate alpha-synuclein aggregation and drive progressive dopaminergic neuron loss. Pharmacological inhibition will attenuate neurodegeneration and improve functional outcomes.
Study Design
Phase 1: Preclinical Validation (In vitro + In vivo)
A. In vitro: iPSC-Derived Models
| Parameter | Details |
|-----------|---------|
| Model | iPSC-derived microglia + dopaminergic neurons from PD patients (LRRK2 G2019S, idiopathic, GBA carriers) and healthy controls |
| Condition Groups | Control, PD neurons only, PD neurons + cGAS activators (dsDNA transfection), PD neurons + cGAS-STING inhibitors (G150, H151) |
| Readouts | - cGAS, STING, p-STING expression (Western blot, immunofluorescence) - cGAMP production (mass spectrometry) - IFN-β, ISG expression (qPCR, ELISA) - α-synuclein aggregation (pSer129) - Neuronal survival (MAP2+ counts, TUNEL) - Mitochondrial function ( Seahorse) |
B. In vivo: Mouse Models
...Study Overview
Objective: Validate cGAS-STING pathway activation as a mechanistically significant driver of dopaminergic neurodegeneration in PD and test therapeutic targeting with cGAS/STING inhibitors.
Hypothesis: Chronic cGAS-STING activation in microglia and neurons driven by cytosolic DNA accumulation (primarily mitochondrial DNA) triggers type I interferon responses that accelerate alpha-synuclein aggregation and drive progressive dopaminergic neuron loss. Pharmacological inhibition will attenuate neurodegeneration and improve functional outcomes.
Study Design
Phase 1: Preclinical Validation (In vitro + In vivo)
A. In vitro: iPSC-Derived Models
| Parameter | Details |
|-----------|---------|
| Model | iPSC-derived microglia + dopaminergic neurons from PD patients (LRRK2 G2019S, idiopathic, GBA carriers) and healthy controls |
| Condition Groups | Control, PD neurons only, PD neurons + cGAS activators (dsDNA transfection), PD neurons + cGAS-STING inhibitors (G150, H151) |
| Readouts | - cGAS, STING, p-STING expression (Western blot, immunofluorescence) - cGAMP production (mass spectrometry) - IFN-β, ISG expression (qPCR, ELISA) - α-synuclein aggregation (pSer129) - Neuronal survival (MAP2+ counts, TUNEL) - Mitochondrial function ( Seahorse) |
B. In vivo: Mouse Models
| Parameter | Details |
|-----------|---------|
| Models | MPTP-induced PD model, α-synuclein pre-formed fibril (PFF) model, PINK1 knockout (mtDNA release model) |
| Treatment Groups | Vehicle, cGAS inhibitor (G150, 30mg/kg i.p. daily), STING inhibitor (H151, 10mg/kg i.p. daily), Positive control (L-DOPA) |
| Duration | 4 weeks post-MPTP, 8 weeks post-PFF injection |
| Readouts | - Behavioral: cylinder test, stepping test, gait analysis, rotarod - Biochemical: striatal dopamine, TH+ neuron counts in SNc - Molecular: cGAS-STING pathway activation (cGAMP, p-STING) - Type I IFN markers: IFN-β, ISG56 - Inflammation: Iba1+ microglial density, cytokine levels - α-synuclein pathology: pSer129 burden |
Phase 2: Biomarker Development (Clinical)
A. Biomarker Discovery
| Parameter | Details |
|-----------|---------|
| Cohort | 120 PD patients (de novo, early-stage), 60 healthy controls |
| Samples | CSF, plasma, peripheral blood mononuclear cells (PBMCs) |
| Biomarkers | cGAMP (CSF and plasma), STING, p-STING, IFN-β, ISG56, CXCL10 in CSF; genetic variants in cGAS/STING genes |
| Correlation | UPDRS motor score, MoCA, DAT-SPECT imaging, disease progression rate |
B. Clinical Validation
| Parameter | Details |
|-----------|---------|
| Design | Cross-sectional, multi-center |
| Cohort | 400 PD patients (various stages), 150 controls |
| Primary Endpoint | Biomarker levels vs. clinical measures |
| Secondary | Biomarker changes over 24-month follow-up |
Phase 3: Clinical Trial (Proof-of-Concept)
A. Study Design
| Parameter | Details |
|-----------|---------|
| Design | Randomized, double-blind, placebo-controlled |
| Population | Early-stage PD (Hoehn & Yahr 1-2) with elevated cGAMP or IFN markers |
| Intervention | STING inhibitor (to be determined based on BBB penetration) or placebo |
| Duration | 52 weeks |
| Sample Size | 80 patients (40 per arm) |
| Primary Endpoints | - Change in UPDRS Part III (motor) - Change in CSF cGAMP and IFN-β |
| Secondary Endpoints | - DAT-SPECT progression - MoCA cognitive scores - Quality of life (PDQ-39) - Biomarker response |
Study Flowchart
Mermaid diagram (expand to render)
Primary Endpoints
Preclinical
cGAS-STING Activation: Significant increase in cGAS, p-STING, cGAMP in PD models vs. controls
Type I IFN Response: Elevated IFN-β and ISG expression in PD neurons and mouse brain
Neuroprotection: cGAS-STING inhibitor treatment reduces neuron loss by ≥35%
α-Synuclein Modulation: Reduced pSer129 aggregation with inhibitor treatmentClinical
Biomarker Correlation: CSF cGAMP levels correlate with motor severity (r ≥ 0.4)
Treatment Effect: STING inhibitor reduces IFN biomarkers by ≥25% vs. baselinePower Analysis
Preclinical (In vivo)
- Effect Size: 35% reduction in neuron loss with treatment
- α: 0.05
- Power: 0.80
- n per group: 15 mice
Clinical Biomarker Study
- Expected correlation: r = 0.4
- α: 0.05
- Power: 0.80
- n: 120 PD patients
Clinical Trial
- Expected difference: 4 points UPDRS Part III
- SD: 10 points
- α: 0.05, two-sided
- Power: 0.80
- n: 40 per arm (accounting for 20% dropout)
Ethical Considerations
Animal Use: 3R principles (replacement, reduction, refinement)
Human Subjects: IRB approval, informed consent, data safety monitoring board
Risk Mitigation: Use STING inhibitors with established safety profilesTimeline
| Phase | Duration | Milestone |
|-------|----------|-----------|
| Phase 1A (iPSC) | 9 months | Validated in vitro model |
| Phase 1B (animal) | 15 months | Preclinical proof-of-concept |
| Phase 2 | 18 months | Biomarker validation complete |
| Phase 3 | 36 months | Phase I/II trial complete |
Budget Estimate
| Phase | Cost (USD) |
|-------|------------|
| Phase 1 | $1.8M |
| Phase 2 | $1.2M |
| Phase 3 | $6.5M |
| Total | $9.5M |
Risk Assessment
| Risk | Likelihood | Mitigation |
|------|------------|------------|
| Inadequate BBB penetration of inhibitors | High | Prioritize BBB-penetrant STING inhibitors; prodrug strategies |
| Pathway not central in PD | Moderate | Comprehensive mechanistic studies; patient stratification |
| Off-target effects | Low | Selective inhibitors; careful safety monitoring |
| Biomarker assay development needed | Moderate | Develop CSF cGAMP assay with pharma partners |
| Patient recruitment | Moderate | Multi-center design; patient advocacy groups |
Success Criteria
Mechanistic Validation: cGAS-STING activation confirmed as significant contributor to PD neurodegeneration
Biomarker Utility: cGAMP validated as PD progression marker
Therapeutic Efficacy: STING inhibitor shows acceptable safety and preliminary efficacyCross-Links
- [cGAS-STING Hypothesis Page](/hypotheses/cgas-sting-parkinsons)
- [STING1 Protein](/proteins/sting1-protein)
- [DNA Sensing Pathways in Neurodegeneration](/mechanisms/dna-sensing-pathways-neurodegeneration)
- [Mitochondrial DNA Release Mechanism](/mechanisms/mitochondrial-dna-release-neurodegeneration)
- [Neuroinflammation in PD](/mechanisms/neuroinflammation-parkinsons)
- [NLRP3 Inflammasome Hypothesis](/hypotheses/nlrp3-inflammasome-parkinsons)
References
[G150: Potent and selective cGAS inhibitor (2023)](https://pubmed.ncbi.nlm.nih.gov/37243210/)
[H151: Covalent STING inhibitor (2023)](https://pubmed.ncbi.nlm.nih.gov/31865247/)
[Xie et al., Mitochondrial DNA release triggers cGAS-STING (2023)](https://doi.org/10.1038/s41421-023-00039-0)
[Sliter et al., cGAS-STING in aging neurons (2018)](https://doi.org/10.1111/acel.12840)